Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio
Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
Hosted on MSN1d
LNTH: Evergreen Acquisition Promotes Future InnovationLNTH Lantheus to Buy Evergreen Theragnostics Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its second acquisition this ...
Radiopharmaceutical specialist Lantheus Holdings (NASDAQ: LNTH) had some news to report Tuesday morning, but the market ...
Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...
Lantheus (LNTH) announced the appointment of Phuong Khanh Morrow, M.D. to Lantheus’ Board of Directors, effective February 1, 2025. As an ...
Lantheus Holdings, Inc. (LNTH) stock price is 91.13 and Lantheus Holdings, Inc. (LNTH) 10-day simple moving average is 94.66. Lantheus Holdings, Inc. (LNTH) stock price is 91.13 and ...
Massachusetts-based radiopharmaceutical company Lantheus (Nasdaq: LNTH) has announced a plan to acquire clinical-stage ...
Learn more about whether Integra LifeSciences Holdings Corporation or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial ...
Lantheus' Alzheimer's diagnostics market investments present a significant untapped opportunity, potentially adding $1 billion in sales by 2032, enhancing the company's valuation. LNTH has 3 ...
Short interest in Lantheus Holdings Inc (NASDAQ:LNTH) increased during the last reporting period, rising from 4.68M to 6.19M. This put 11.76% of the company's publicly available shares short.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback